Fujirebo

Fujirebio is a premier global in vitro diagnostics (IVD) company specializing in the development and manufacture of high-quality testing reagents and automated systems. The company is a pioneer in the field of neurology biomarkers, particularly for Alzheimer's disease, and maintains a strong portfolio in oncology and infectious diseases. Its flagship Lumipulse platform utilizes fully automated chemiluminescent enzyme immunoassay (CLEIA) technology to provide rapid and precise results in clinical settings. Fujirebio also operates a significant CDMO business, partnering with other healthcare companies to develop and produce diagnostic solutions. Headquartered in Japan, it maintains a robust international presence through subsidiaries in the United States and Europe. The company continues to expand its diagnostic capabilities through strategic acquisitions, such as the 2022 purchase of ADx NeuroSciences.